Johnson & Johnson shares fell as much as 6.8% despite an improved full-year earnings outlook. A sharp decline in reported quarterly profit, weaker-than-expected MedTech performance and litigation-related charges weighed on investor sentiment despite revenue growth and adjusted earnings beating estimates.
Johnson & Johnson stock rout: What's driving the sharp decline?
Published ·
Keep reading
Related stories




